LDK378 for previously treated anaplastic-lymphoma-kinase-positive non-small-cell lung cancer

West MidlandsGeneric Health Relevance
Start Date: 1 Mar 2014

Project summary

To appraise the clinical and cost effectiveness of ceritinib within its marketing authorisation for previously treated anaplastic lymphoma kinase-positive non-small-cell lung cancer.


NICE - National Institute for HEalth and Care Excellence